Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.”
We want to be the prime example of an innovative, science-driven biotech from China, showcasing the best of world capability in terms of innovation, rather than another Chinese me-too company
